With Phase III Trials Planned, Telik Aims To Sell 5M Shares

On the heels of an encouraging meeting with the FDA regarding Phase III trials of the company's drug for ovarian cancer and non-small-cell lung cancer, Telik Inc. said it plans to pull down cash through an offering of about 5 million shares under a shelf registration filed in June. (BioWorld Today)